LUND, Sweden, Oct. 19, 2022 /PRNewswire/ -- Immunovia AB
(Nasdaq Stockholm: IMMNOV) today announced changes to its executive
management team to accelerate the execution of its strategic
priorities.
The new executive management team will be focused on delivering
the next phase of Immunovia's strategy and commercial growth. As of
1 November, the executive management team will be CEO &
President Philipp Mathieu, CFO Karin
Almqvist Liwendahl and CEO of Immunovia's US subsidiary Immunovia
Inc. Jeff Borcherding. In addition,
a new Chief Operating Officer role will be added to the executive
team during the first quarter of 2023.
The leaner organization structure will in particular focus on
the commercial roll-out of the IMMray PanCan-d test in the U.S. and
the strategic R&D partnership with Proteomedix announced
earlier this week.
"We have been taking important steps and made significant
progress in executing on the Company's strategic priorities which I
set out in February. A leaner executive management team will ensure
that the Immunovia team remains focused on executing our strategic
plan and delivering commercial growth," says Philipp Mathieu – CEO, Immunovia.
For more information, please contact:
Philipp Mathieu
CEO and President
philipp.mathieu@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
The information was submitted for publication, through the
agency of the contact person set out above, at 08:30 am
CET on October 19, 2022.
About Immunovia
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available for early detection of pancreatic cancer. The
test has unmatched clinical performance. Commercialization of
IMMray™ PanCan-d started in August
2021 in the USA and IMMray™
PanCan-d is offered as a laboratory developed test (LDT)
exclusively through Immunovia, Inc. For more information see:
www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit https://immunovia.com/
The following files are available for download:
https://mb.cision.com/Main/13121/3650904/1640602.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.co.uk/news-releases/immunovia-announces-executive-management-team-changes-to-accelerate-execution-of-strategic-priorities-301653205.html